Corvus Pharmaceuticals announced on June 11, 2025, the presentation of preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress. The data was presented in a poster session.
The presentation reiterated findings that ITK inhibition, the mechanism of action for soquelitinib, can modulate immune responses relevant to fibrotic diseases. This further supports the broad applicability of soquelitinib beyond its current clinical programs in oncology and atopic dermatitis.
Dissemination of this preclinical evidence at a prominent rheumatology conference aims to increase awareness among the scientific and medical community. This could potentially attract future collaborations or pave the way for clinical development in systemic sclerosis, expanding the drug's market potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.